Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

O’Shaughnessy, Joyce; Schwartzberg, Lee; Danso, Michael A.; Miller, Kathy D.; Rugo, Hope S.; Neubauer, Marcus A.; Robert, Nicholas J.; Hellerstedt, Beth A.; Saleh, Mansoor N.; Richards, Paul; Specht, Jennifer M.; Yardley, Denise A.; Carlson, R. W.; Finn, Richard S.; Charpentier, Eric; García-Ribas, Ignacio; Winer, Eric P.

doi:10.1200/jco.2014.55.2984

Cited by 264 publications

(187 citation statements)

References 23 publications

(6 reference statements)

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…Recent efforts have sought to identify actionable targets in TNBC, including those that may radiosensitize these tumors. A number of inhibitors of peptide growth factor pathways, such as EGF receptor (EGFR), the insulin-like growth factor receptor (IGFR), FGF receptors (FGFR), VEGF pathways, have been studied in numerous clinical trials with limited success (34)(35)(36). Additional targeted therapies, including inhibitors of PI3K, PARP-1, CHK1, AR, and Src, are in various stages of clinical trials in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer

Speers

Zhao

Kothari

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: While effective targeted therapies exist for estrogen receptor-positive and HER2-positive breast cancer, no such effective therapies exist for triple-negative breast cancer (TNBC); thus, it is clear that additional targets for radiosensitization and treatment are critically needed.Experimental Design: Expression microarrays, qRT-PCR, and Western blotting were used to assess MELK RNA and protein expression levels. Clonogenic survival assays were used to quantitate the radiosensitivity of cell lines at baseline and after MELK inhibition. The effect of MELK knockdown on DNA damage repair kinetics was determined using gH2AX staining. The in vivo effect of MELK knockdown on radiosensitivity was performed using mouse xenograft models. Kaplan-Meier analysis was used to estimate local control and survival information, and a Cox proportional hazards model was constructed to identify potential factors impacting local recurrence-free survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer

Speers

Zhao

Kothari

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Surgery and chemotherapy are the major treatment methods for breast cancer. To extend survival as much as possible, chemotherapy without surgical treatment is more appropriate for late-stage breast cancer [3,4]. The most preferred chemotherapeutic drugs are anthracyclines and taxanes, but their toxicity and side effects can severely reduce treatment effectiveness andquality of life for elderly patients most such patients are intolerant of combined chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Comparison of capecitabine and tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma in the elderly

Zheng¹,

Jin²,

Liu³

2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…In general, the use of single agent chemotherapy is preferred in most cases of MBC [48]. However, the National Comprehensive Cancer Network guidelines suggested the use of combination treatments in TNMBC [70,71]. Platinum agents in combination with other chemotherapy has established an antitumor activity in TNMBC [72,73].…”

Section: Taxane and Nab-paclitaxel Use In Triple Negative Metastatic mentioning

confidence: 99%

“…However, the National Comprehensive Cancer Network guidelines suggested the use of combination treatments in TNMBC [70,71]. Platinum agents in combination with other chemotherapy has established an antitumor activity in TNMBC [72,73]. A small randomized phase II study for first line therapy was carried out on 53 female with TNMBC.…”

Section: Taxane and Nab-paclitaxel Use In Triple Negative Metastatic mentioning

confidence: 99%

Untitled

2017

MOJCSR

View full text Add to dashboard Cite

Breast cancer (BC) remains the most invasive diagnosed cancers among female, affecting 25% of total number of cancers worldwide. Systematic chemotherapies still remain one of the effective treatments for BC. One of the common and powerful chemotherapies that have been used in the past decade is taxane. Taxane are a class of anticancer compounds that are known to cause cell cycle arrest and apoptosis induction (cell death). They are used for the treatment of malignant tumors specifically BC along with other chemotherapies such as anthracycline. However, the neurotoxic effects that are associated with the use of taxane are still challenging. Recently, nanoparticle albumin bound taxane (nab-paclitaxel) was developed, resulting in lowering of the side effects that are associated with the use of taxane and enhancing its delivery to the targeted cancer cells. Nab-paclitaxel has been subjected to several clinical trials to evaluate its efficacy in the treatment of various types of cancers including BC. The results indicated that nab-paclitaxel showed an improved efficacy and promising outcomes in the treatment of various forms of BC. This review focuses on the comparison of classical taxane to the new generation, nab-paclitaxel chemotherapy, with emphasis on their comparative efficacy in metastatic BC (MBC) and triple negative metastatic BC (TNMBC) treatment, concluding that nab-paclitaxel has improved efficacy, safety data and with a more convenient administration confirming an optimal treatment option for patients in both cases. Future work is needed to optimize dosing schedules and combination regimens of nab-paclitaxel, which could broaden the clinical utility of this agent.

show abstract

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Abstract: The trial did not meet the prespecified criteria for the coprimary end points of PFS and OS in the ITT population. The potential benefit with iniparib observed in second-/third-line subgroup warrants further evaluation.

Cited by 264 publications

References 23 publications

Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer

Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer

Comparison of capecitabine and tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma in the elderly

Untitled

Contact Info

Product

Resources

About